Lee S. Schwartzberg MD, FACP
Chief, Medical Oncology and Hematology, Renown Institute for Cancer, and Professor of Clinical Medicine, University of Nevada, Reno, NevadaDr. Lee Schwartzberg is Chief, Medical Oncology and Hematology at the Renown Institute for Cancer and Professor of Clinical Medicine at the University of Nevada, Reno. He completed his hematology/oncology fellowship at Memorial Sloan Kettering Cancer Center and spent 3 decades at West Cancer Center and Research Institute as Medical Director. He was Chief, Division of Hematology/Oncology and Professor of Medicine at the University of Tennessee Health Science Center from 2012 to 2017.
In 2018, he became the founding Chief Medical Officer of OneOncology, a national oncology practice management company and served in that role through 2021. He previously served on the Board of Directors and the Guideline Steering Committee of the National Comprehensive Cancer Network and participated in several guideline committees, including the committee for breast cancer.
Dr. Schwartzberg has published nearly 300 peer-reviewed manuscripts, book chapters, and monographs. He is the founding Editor-in-Chief of the Elsevier website PracticeUpdate Oncology and the founding Editor-in-Chief of the journal Community Oncology. His research interests focus on breast cancer, supportive care, precision medicine, and patient-reported outcomes. Dr. Schwartzberg maintains a clinical practice in breast cancer.
Disclosures
- Consultant: Amgen; Pfizer; Helsinn; Genentech; BMS (Bristol; Myer; Squibb); Myriad; AstraZeneca; Spectrum; Napo
- Advisory boards: Genomic Health Research Funding (Institution): Amgen; DSMB: Bayer
Recent Contributions to PracticeUpdate:
- Intravenous and Oral NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting Among Breast Cancer Patients
- Pertuzumab, Trastuzumab, and Docetaxel for HER2-Positive Metastatic Breast Cancer
- Pembrolizumab for Early Triple-Negative Breast Cancer
- Standard Anthracycline-Based vs Docetaxel–Capecitabine in Early High–Clinical and/or –Genomic Risk Breast Cancer
- Association of Germline Genetic Testing Results With Locoregional and Systemic Therapy in Patients With Breast Cancer
- Biosimilars for HER2-Targeted Antibodies
- High-Dose Chemotherapy With HSCT for High-Risk Breast Cancer and Four or More Involved Axillary Lymph Nodes
- Endocrine Therapy ± Whole Breast Irradiation in Low-Risk Breast Cancer Patients After Breast-Conserving Surgery
- Predicting Thrombocytopenia in Patients With Breast Cancer Treated With Ado-Trastuzumab Emtansine
- Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer